Literature DB >> 21280220

Tyrosine 656 in topoisomerase IIβ is important for the catalytic activity of the enzyme: Identification based on artifactual +80-Da modification at this site.

Adrian G Grozav1, Belinda B Willard, Toshiyuki Kozuki, Kenichi Chikamori, Marius A Micluta, Andrei-Jose Petrescu, Michael Kinter, Ram Ganapathi, Mahrukh K Ganapathi.   

Abstract

Topoisomerase (topo) II catalyzes topological changes in DNA. Although both human isozymes, topo IIα and β are phosphorylated, site-specific phosphorylation of topo IIβ is poorly characterized. Using LC-MS/MS analysis of topo IIβ, cleaved with trypsin, Arg C or cyanogen bromide (CNBr) plus trypsin, we detected four +80-Da modified sites: tyr656, ser1395, thr1426 and ser1545. Phosphorylation at ser1395, thr1426 and ser1545 was established based on neutral loss of H(3) PO(4) (-98 Da) in the CID spectra and on differences in 2-D-phosphopeptide maps of (32) P-labeled wild-type (WT) and S1395A or T1426A/S1545A mutant topo IIβ. However, phosphorylation at tyr656 could not be verified by 2-D-phosphopeptide mapping of (32) P-labeled WT and Y656F mutant protein or by Western blotting with phosphotyrosine-specific antibodies. Since the +80-Da modification on tyr656 was observed exclusively during cleavage with CNBr and trypsin, this modification likely represented bromination, which occurred during CNBr cleavage. Re-evaluation of the CID spectra identified +78/+80-Da fragment ions in CID spectra of two peptides containing tyr656 and tyr711, confirming bromination. Interestingly, mutation of only tyr656, but not ser1395, thr1326 or ser1545, decreased topo IIβ activity, suggesting a functional role for tyr656. These results, while identifying an important tyrosine in topo IIβ, underscore the importance of careful interpretation of modifications having the same nominal mass.
Copyright © 2011 WILEY-VCH Verlag GmbH & Co. KGaA, Weinheim.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21280220      PMCID: PMC3608106          DOI: 10.1002/pmic.201000194

Source DB:  PubMed          Journal:  Proteomics        ISSN: 1615-9853            Impact factor:   3.984


  48 in total

1.  Biochemical and pharmacological properties of p170 and p180 forms of topoisomerase II.

Authors:  F H Drake; G A Hofmann; H F Bartus; M R Mattern; S T Crooke; C K Mirabelli
Journal:  Biochemistry       Date:  1989-10-03       Impact factor: 3.162

2.  Large-scale characterization of HeLa cell nuclear phosphoproteins.

Authors:  Sean A Beausoleil; Mark Jedrychowski; Daniel Schwartz; Joshua E Elias; Judit Villén; Jiaxu Li; Martin A Cohn; Lewis C Cantley; Steven P Gygi
Journal:  Proc Natl Acad Sci U S A       Date:  2004-08-09       Impact factor: 11.205

3.  Threonine 1342 in human topoisomerase IIalpha is phosphorylated throughout the cell cycle.

Authors:  R Ishida; M Iwai; K L Marsh; C A Austin; T Yano; M Shibata; N Nozaki; A Hara
Journal:  J Biol Chem       Date:  1996-11-22       Impact factor: 5.157

4.  Proliferation- and cell cycle-dependent differences in expression of the 170 kilodalton and 180 kilodalton forms of topoisomerase II in NIH-3T3 cells.

Authors:  R D Woessner; M R Mattern; C K Mirabelli; R K Johnson; F H Drake
Journal:  Cell Growth Differ       Date:  1991-04

Review 5.  Physiological regulation of eukaryotic topoisomerase II.

Authors:  R J Isaacs; S L Davies; M I Sandri; C Redwood; N J Wells; I D Hickson
Journal:  Biochim Biophys Acta       Date:  1998-10-01

6.  Different patterns of gene expression of topoisomerase II isoforms in differentiated tissues during murine development.

Authors:  G Capranico; S Tinelli; C A Austin; M L Fisher; F Zunino
Journal:  Biochim Biophys Acta       Date:  1992-08-17

7.  Novel HeLa topoisomerase II is the II beta isoform: complete coding sequence and homology with other type II topoisomerases.

Authors:  C A Austin; J H Sng; S Patel; L M Fisher
Journal:  Biochim Biophys Acta       Date:  1993-03-20

8.  Topoisomerase II alpha and topoisomerase II beta genes: characterization and mapping to human chromosomes 17 and 3, respectively.

Authors:  K B Tan; T E Dorman; K M Falls; T D Chung; C K Mirabelli; S T Crooke; J Mao
Journal:  Cancer Res       Date:  1992-01-01       Impact factor: 12.701

9.  The distribution and expression of the two isoforms of DNA topoisomerase II in normal and neoplastic human tissues.

Authors:  H Turley; M Comley; S Houlbrook; N Nozaki; A Kikuchi; I D Hickson; K Gatter; A L Harris
Journal:  Br J Cancer       Date:  1997       Impact factor: 7.640

10.  Topoisomerase II: A specific marker for cell proliferation.

Authors:  M M Heck; W C Earnshaw
Journal:  J Cell Biol       Date:  1986-12       Impact factor: 10.539

View more
  1 in total

1.  Roles of the C-terminal domains of topoisomerase IIα and topoisomerase IIβ in regulation of the decatenation checkpoint.

Authors:  Toshiyuki Kozuki; Kenichi Chikamori; Marius D Surleac; Marius A Micluta; Andrei J Petrescu; Eric J Norris; Paul Elson; Gerald A Hoeltge; Dale R Grabowski; Andrew C G Porter; Ram N Ganapathi; Mahrukh K Ganapathi
Journal:  Nucleic Acids Res       Date:  2017-06-02       Impact factor: 16.971

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.